Ascendis Pharma A/S (NASDAQ:ASND) Given New $262.00 Price Target at Wells Fargo & Company

Ascendis Pharma A/S (NASDAQ:ASND) had its target price hoisted by Wells Fargo & Company from $260.00 to $262.00 in a report published on Friday morning, Benzinga reports. The firm currently has an overweight rating on the biotechnology company’s stock.

Other equities research analysts have also recently issued reports about the company. Cantor Fitzgerald reiterated an overweight rating and issued a $173.00 target price on shares of Ascendis Pharma A/S in a report on Friday. Morgan Stanley reiterated an equal weight rating and set a $116.00 target price on shares of Ascendis Pharma A/S in a report on Monday, April 22nd. Citigroup raised their target price on shares of Ascendis Pharma A/S from $146.00 to $182.00 and gave the company a buy rating in a research report on Thursday, February 8th. Wedbush upped their price target on shares of Ascendis Pharma A/S from $207.00 to $225.00 and gave the stock an outperform rating in a research report on Thursday, February 8th. Finally, JPMorgan Chase & Co. increased their price objective on shares of Ascendis Pharma A/S from $167.00 to $170.00 and gave the company an overweight rating in a research note on Friday. Two research analysts have rated the stock with a hold rating and seven have given a buy rating to the stock. Based on data from MarketBeat, the company has a consensus rating of Moderate Buy and an average price target of $173.88.

Ascendis Pharma A/S Price Performance

Ascendis Pharma A/S stock opened at $137.20 on Friday. The stock has a market cap of $7.99 billion, a price-to-earnings ratio of -14.28 and a beta of 0.54. The firm has a 50-day moving average of $146.67 and a two-hundred day moving average of $128.07. Ascendis Pharma A/S has a 1 year low of $83.75 and a 1 year high of $161.00.

Ascendis Pharma A/S (NASDAQ:ASND) last posted its quarterly earnings results on Wednesday, February 7th. The biotechnology company reported ($1.66) earnings per share for the quarter, beating the consensus estimate of ($2.15) by $0.49. Ascendis Pharma A/S had a negative net margin of 152.68% and a negative return on equity of 16,574.15%. The firm had revenue of $148.62 million during the quarter, compared to the consensus estimate of $97.02 million. Research analysts expect that Ascendis Pharma A/S will post -4.15 earnings per share for the current year.

Institutional Investors Weigh In On Ascendis Pharma A/S

Several institutional investors have recently bought and sold shares of the company. Certuity LLC acquired a new position in shares of Ascendis Pharma A/S during the fourth quarter worth $270,000. Invesco Ltd. raised its stake in Ascendis Pharma A/S by 9.3% in the third quarter. Invesco Ltd. now owns 672,126 shares of the biotechnology company’s stock valued at $62,938,000 after buying an additional 57,413 shares during the last quarter. J.P. Morgan Private Wealth Advisors LLC acquired a new stake in Ascendis Pharma A/S in the third quarter worth about $1,810,000. Schonfeld Strategic Advisors LLC grew its stake in shares of Ascendis Pharma A/S by 24.7% during the third quarter. Schonfeld Strategic Advisors LLC now owns 38,900 shares of the biotechnology company’s stock worth $3,643,000 after acquiring an additional 7,700 shares during the last quarter. Finally, Sequoia Financial Advisors LLC acquired a new position in shares of Ascendis Pharma A/S during the fourth quarter valued at about $732,000.

About Ascendis Pharma A/S

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates.